Johnson and Johnson will pay $5.5 billion to resolve roughly 69,000 talc lawsuits consolidated in New Jersey federal court along with related state cases, a deal that captures 99.75 percent of remaining claims and finally lets the company close a litigation chapter that has dragged on for more than a decade. The settlement, valued at €4.8 billion, still requires approval from the judge overseeing the federal multidistrict litigation.
The agreement arrives just days after a federal judge cast doubt on individual plaintiffs' ability to prove that talc specifically caused their ovarian cancer, a ruling that strengthened J&J's hand considerably. That victory came after the litigation resumed in March 2025, emerging from a freeze of more than three years during which J&J repeatedly tried and failed to shunt the liabilities into a shell company's bankruptcy, a maneuver the courts ultimately rejected.
Plaintiffs' firms signed off on the deal, calling it a good resolution after ten years of battle. J&J's vice president of litigation Erik Haas described the claims as meritless and noted the company has prevailed in the vast majority of cases actually tried to verdict. The company has long maintained its talc is safe and asbestos-free, and stopped selling talc-based baby powder in the United States in 2020 in favor of a cornstarch alternative.
Unlike the collapsed bankruptcy proposals, this settlement covers only existing claims and creates no mechanism for future lawsuits. That distinction matters: every new diagnosis becomes a new fight, and J&J has effectively bet that the recent judicial skepticism toward causation will make those fights winnable one by one.
The $5.5 billion price tag is substantial but J&J has signaled it can absorb the hit without derailing its mission to develop medicines and devices that save lives, as Haas put it. What makes the deal notable is not the cash but the closure, J&J is paying a premium to avoid the spectacle of endless trials and the tail risk of a runaway verdict, even while insisting it would win most of them. The market has long priced in a talc liability; this simply moves the line item from contingent to certain.
Now the judge decides. If the court blesses the agreement, J&J walks away from the mass tort with a defined cost and no future claims facility. If not, the company returns to the docket it just tried to escape, armed with a stronger causation precedent but no global resolution. Either way, the cornstarch stays on the shelf.